Tharimmune, Inc. (THAR) - Utang jangka dawa marang modal

Tharimmune, Inc. relies on the development of precision antibodies to combat metastases, establishing a foundation for leadership. The GURU.Markets service features a linear chart of the long-term debt-to-equity ratio, where the value 0.00 indicates the status of the parameter. However, geopolitical disruptions are hindering drug certification, and the pre-commercial status of its developments makes the company's market advantages dependent on test results.

A fundamental assessment of the balance sheet structure allows for the minimization of capital loss risks during market volatility. For Tharimmune, Inc. (THAR), which develops complex immunotherapy methods, financial autonomy is critical during prolonged scientific research and development. This ratio of long-term liabilities to equity measures the proportion of long-term loans relative to the company's net assets. A decrease in this coefficient confirms the company's resilience to external borrowing. While low leverage ensures security, it may indicate a conservative pace of business scaling.